Today: 27 April 2026
Mortgage Rates Today: 30-Year Fixed Dips to 6.43%, but Spring Buyers Get Little Relief
6 April 2026
2 mins read

Mortgage Rates Today: 30-Year Fixed Dips to 6.43%, but Spring Buyers Get Little Relief

WASHINGTON, April 6, 2026, 15:08 EDT

Monday saw U.S. mortgage rates edge lower, though the move was slight. The daily index from Mortgage News Daily showed the average top-tier 30-year fixed rate at 6.43%, just 2 basis points—0.02 percentage point—below the previous level.

Borrowing costs remain stubbornly elevated during what’s typically the peak period for homebuyers. Freddie Mac’s latest weekly read put the 30-year fixed mortgage at 6.46%—a level not seen since early September. Meanwhile, purchase applications slid 3%, according to the Mortgage Bankers Association’s most recent data.

Long-term yields are setting the tone. The 10-year Treasury yield sat near 4.34% on Mortgage News Daily. Reuters flagged March services-sector prices at 70.7—the highest mark since October 2022. That mix has traders betting the Federal Reserve holds off on rate cuts for now.

Monday’s modest decline didn’t look convincing. Wells Fargo Investment Institute is now forecasting zero Fed rate cuts in 2026, scrapping its previous call. Citigroup also pushed its expectations for rate cuts to September, October, and December, a shift prompted by hotter jobs numbers and persistent inflation concerns.

Where you look matters: Bankrate’s daily read put the 30-year fixed at 6.50% on Monday. Zillow Home Loans, with its sample 30-year quote including points—those upfront charges that tweak your rate—came in lower at 6.25%. Freddie Mac, meanwhile, bases its weekly number on traditional purchase loans for buyers with at least 20% down and solid credit.

Household budgets are feeling the strain. According to Redfin, the median monthly mortgage payment in the U.S. hit $2,742 over the four weeks ending March 29—a year-over-year gain that breaks a nearly half-year streak of declines. Pending home sales slipped 1.2%. Sellers outnumbered buyers by about 630,000 during the same period.

Mike Fratantoni, chief economist at the MBA, pointed to “the shocks of the jump in rates and the increase in overall economic uncertainty” as factors likely weighing on buyer confidence. Freddie Mac’s Sam Khater, also chief economist, separately advised borrowers to collect several offers, noting that shopping around for rates remains a way to save “thousands of dollars.” MBA Newslink

Without a clear shift in Middle East tensions, mortgage rates probably won’t dip below 6.5%, according to Stephen Kates, financial analyst at Bankrate. That fleeting dip under 6% back in February? Gone, replaced by “a more cautious, high-volatility climate,” said Bright MLS chief economist Lisa Sturtevant. Bankrate

Friday’s payrolls number didn’t move the needle for everyone. Chen Zhao, who leads economics research at Redfin, said in a note after the jobs data that the report probably won’t shift rates much. “The Fed will remain on hold,” Zhao wrote, pointing to uncertainty around the length and impact of the war with Iran. Redfin

The next hurdle isn’t far off. The Labor Department’s March consumer price data lands Friday, April 10. Treasury rolls out a $39 billion 10-year note auction April 8, followed by a $22 billion 30-year bond sale a day later. Mortgage rates, which often shadow long-term Treasury yields, could be on the move if inflation surprises to the upside or if demand stumbles at those auctions—either could send mortgage quotes climbing.

A bit of short-term relief has surfaced, but it doesn’t shift the big picture. Matthew Graham at Mortgage News Daily pointed out last week that rates peaked on March 27 before lenders dropped them to the lowest since March 18. That dip made Monday’s market feel slightly less strained, though it hasn’t solved the deeper affordability squeeze.

Stock Market Today

  • FG Nexus Series A Preferred Stock Yield Surpasses 8% Amid Market Dip
    April 27, 2026, 4:11 PM EDT. Shares of FG Nexus Inc's 8.00% Series A Cumulative Preferred Stock (FGNXP) yielded over 8% on Monday, with prices falling to $24.95. This yield exceeds the 6.98% average in the Insurance Brokers preferred stock segment, per Preferred Stock Channel data. FGNXP trades close to its liquidation preference at a 0.40% discount, much narrower than the 17% category average. Meanwhile, FGNXP shares dropped about 3.8%, even as FG Nexus common shares (FGNX) rose roughly 0.7%. The preferred stock's dividend rate is annualized at $2.00. Investors observe this yield mark as an indicator of income potential within preferred stocks, which offer fixed dividends and priority in liquidation. The overall market context shows a divergence between preferred and common shares' performance on the same day.

Latest article

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

27 April 2026
Intellia Therapeutics reported its CRISPR drug lonvo-z cut hereditary angioedema attacks by 87% versus placebo in a late-stage trial, with 62% of treated patients attack- and therapy-free over six months. The company has started a rolling U.S. approval application. No serious adverse events were reported. Intellia shares fell 0.9% to $13.51 after initial gains.
U.S. Energy Corp Stock Jumps as $285 Helium Deal Gives Big Sky a Buyer

U.S. Energy Corp Stock Jumps as $285 Helium Deal Gives Big Sky a Buyer

27 April 2026
U.S. Energy Corp. signed a five-year helium sales deal with an unnamed global industrial gas company, securing a buyer for output from its planned Big Sky Carbon Hub in Montana. The contract covers up to 1.2 million cubic feet a month at a fixed $285 per thousand cubic feet, with inflation adjustments starting March 2028. U.S. Energy shares rose 20.8% to $1.12 on heavy volume. The agreement is “take-or-pay,” with the buyer handling pickup at the plant.
Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

27 April 2026
Veradermics shares rose 40% Monday after its oral hair-loss drug VDPHL01 met all main goals in a Phase 2/3 trial of 519 men. Patients taking the drug saw average hair count increases of 30.3 to 33.0 hairs per square centimeter over six months, compared to 7.3 for placebo. No treatment-related serious or heart-related adverse events were reported.
Bitcoin Price Nears $70,000 as Iran Ceasefire Talks Spark Risk Rally
Previous Story

Bitcoin Price Nears $70,000 as Iran Ceasefire Talks Spark Risk Rally

UnitedHealth Stock Gets Lift Ahead of Q1 Earnings After Medicare Advantage Rate Boost
Next Story

UnitedHealth Stock Gets Lift Ahead of Q1 Earnings After Medicare Advantage Rate Boost

Go toTop